Cellnex Telecom (CLNX) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
15 Jan, 2026Executive summary
Revenues for the first nine months of 2024 reached €2,903 million, up 7% year-over-year, with organic revenue growth of 7.4% and strong operational execution.
Organic EBITDAAL increased 9.8% year-over-year to €1,723 million, with margin improving to 59%.
Free cash flow was €326 million, down from €436 million in 9M 2023, mainly due to lower remedies proceeds and recurring dividends to minorities.
Portfolio optimization continues, with asset sales in Ireland and Austria progressing and expected to close by Q1 2025 and mid-December 2024, respectively.
Net result improved to €140 million from a loss of €198 million in 9M 2023, despite impairment and classification of Austrian assets as held for sale.
Financial highlights
Total revenues ex-pass throughs reached €2,903 million (+7.0% vs. 9M 2023); organic revenues growth +7.4%.
EBITDAAL at €1,723 million (+8.9% vs. 9M 2023); margin at 59%.
Adjusted EBITDA at €2,386 million (+6%); adjusted EBITDA margin at 82%.
Recurring levered free cash flow reached €1,256 million (+7%).
Net financial debt stood at approximately €17,500 million as of September 2024, with 80% at fixed rates and €4 billion in immediate liquidity.
Outlook and guidance
2024 guidance reiterated: revenues ex-pass throughs €3,850–3,950 million, adjusted EBITDA €3,150–3,250 million, RLFCF €1,650–1,750 million, FCF €250–350 million.
On track to meet short- and medium-term targets, with acceleration of shareholder returns expected after asset sales in Austria and Ireland.
Commitment to maintaining investment grade rating and leverage targets while considering increased shareholder remuneration in 2025.
Latest events from Cellnex Telecom
- Net profit jumped to €136.5M, with €1.3B buybacks and strong revenue and margin growth.CLNX
Q4 202527 Feb 2026 - Revenue and EBITDA growth continued, but net loss widened on Austrian impairment; guidance reaffirmed.CLNX
Q2 20242 Feb 2026 - Revenue, EBITDA, and cash flow surged; €800M buyback and dividend policy boost returns.CLNX
Q4 20247 Jan 2026 - Strong Q1 growth, portfolio streamlining, and robust buyback amid resilient sector outlook.CLNX
Q1 202518 Nov 2025 - Strong growth, margin gains, and EUR 1B shareholder returns reaffirm guidance and resilience.CLNX
Q3 20257 Nov 2025 - Solid H1 2025 growth, enhanced cash flow, and resilient long-term contracts drive outlook.CLNX
Q2 202531 Oct 2025